Background. -Elevated blood pressure is one of the most important modifiable risk factors for cardiovascular diseases. Aim. -To evaluate blood pressure management in Côte d'Ivoire. Methods. -A retrospective study was conducted among 2575 hypertensive patients from the Institute of Cardiology of Abidjan, who were followed for at least 10 years, between January 2000 and December 2009. Results. -The patients' mean age ± standard deviation was 59.1 ± 12.5 years; 54.3% were women. At first presentation, hypertension was stage 1 in 21.7%, stage 2 in 32.3% and stage 3 in 46.0% of patients. According to the European guidelines' stratification of the cardiovascular risk-excess attributable to high blood pressure, 46.7% had a very high added risk, 37.8% had a high added risk and 14.9% had a low-to-moderate added risk. Pharmacological therapy was prescribed in 97.8% of patients; more than 66% were receiving at least two antihypertensive drugs, including fixed-dose combination drugs. The most common agents used were diuretics (59.7%) followed by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (59.6%). The most common agents for monotherapy were calcium antagonists. When two or 
more drugs were used, diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were most commonly used. Blood pressure control was achieved in 43.7% of cases. Conclusion. -In our series, severe hypertension with high added risk or very high added risk was very common. Treatment -mostly diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers -required at least two antihypertensive drugs to meet the recommended blood pressure target. © 2011 Elsevier Masson SAS. All rights reserved.
Background
Hypertension is an important worldwide public health challenge because it is one of the most common chronic conditions [1, 2] . In a worldwide survey, 26.4% of the adult population in 2000 had hypertension and 29.2% were projected to have this condition by 2025. The estimated total number of adults with hypertension in 2000 was 972 million and 639 million in economically developing countries [1] . The prevalence of hypertension in Sub-Saharan Africa (SSA) is between 12.5% and 26.9% [3] . In 2005 the World Health Organization's stepwise approach to the surveillance of noncommunicable disease risk factors established a prevalence of hypertension in Côte d'Ivoire of 21.7% [4] .
Hypertension is a major risk factor for cardiovascular disease [5] [6] [7] ; it remains an important cause of coronary heart disease, cerebrovascular disease, peripheral artery disease and heart failure [8] . The 2002 World Health Report estimated that around 11% of the entire disease burden in developed countries was caused by raised blood pressure, and that more than 50% of coronary heart diseases and almost 75% of strokes arose as a result of elevated systolic blood pressure [9] . In SSA, the mortality among patients hospitalized for hypertension-related disorders is over 20% [10] . Unfortunately the particular context of SSA, with its poverty and illiteracy, contributes to the low awareness and suboptimal control and treatment of hypertension [11, 12] . These facts underscore that screening and effective treatment for hypertension should be given higher priority in health policies in this region. It was in this context that we undertook this study at the Institute of Cardiology of Abidjan (ICA), the single university hospital managing cardiovascular diseases in Côte d'Ivoire. The study aimed to describe characteristics, risk factors, treatment and blood pressure control in adult hypertensive patients.
Methods
We undertook a retrospective descriptive study involving patients seen in outpatient clinics at the ICA. The study period spans 10 years, between January 2000 and December 2009. The study population comprised hypertensive adults (aged at least 18 years) with a regular follow-up at the ICA within 1 year. This series included patients who had been receiving initial treatment upon referral to our centre.
We used the standard definition and classification of hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) [7] . The data collected were age, sex and level of blood pressure at initial presentation and, during follow-up, the coexistence of other cardiovascular risk factors, the impact of hypertension and treatment modalities. The following additional cardiovascular risk factors were documented when present: current smoking, dyslipidaemia, diabetes and obesity. Obesity was defined as body mass index greater than 30 kg/m 2 . Waist circumference was recorded when available. Dyslipidaemia was defined according to our biochemistry laboratory standard (total cholesterol > 200 mg/dL or lowdensity lipoprotein cholesterol > 140 mg/dL or high-density lipoprotein cholesterol < 40 g/L). Diabetic patients were informed and treated for diabetes according to standard clinical practice. New diabetic patients detected at the ICA were diagnosed based on the standard value in our laboratory (fasting plasma glucose > 126 mg/dL on repeated measurement). The overall management of diabetes was coordinated by the individual patient's physician and not by the cardiology staff of the ICA.
Assessment of the impact of hypertension systematically included electrocardiography and plasma creatinine measurement. All strokes were documented by a brain computerized tomography scan. Echocardiography was frequently performed and the results were included in the data collection. Finally, if other tests were seldom performed (e.g. albuminuria, microalbuminuria, fundoscopy and 24-hour ambulatory blood pressure) they were not used for analysis.
The ESH/ESC categorization of total risk as low, moderate, high and very high added risk has the merit of simplicity and was therefore chosen for risk stratification [7] . In addition, we focused on the evolution of blood pressure during follow-up. Blood pressure control was defined as a treated systolic blood pressure less than 140 mmHg and diastolic blood pressure less than 90 mmHg, and was ascertained by direct measurement of blood pressure.
Data analysis was conducted using Statistical Package for Social Sciences (SPSS) software, version 17. Univariate analysis was performed for significant associations. A P value ≤ 0.05 was considered for statistical significance.
Results
There were 2575 patients (54.3% women) with a mean age ± standard deviation (SD) of 59.1 ± 12.5 years (range: 18-89 years). At first presentation, mean blood pressure was 169/102 mmHg (range: 120/80 to 250/130 mmHg), with inappropriate control in 90.5% of patients. The hypertension was classified as stage 1 in 21.7%, stage 2 in 32.3% and stage 3 in 46.0% of patients. Blood pressure levels were similar in all age groups (P = 0.18). Stage 3 hypertension was the most common in all age categories (Fig. 1) .
Overall, patients had been diagnosed with hypertension for a mean duration ± SD of 8.8 ± 5.3 years (range: 1-15 years) at the time of their initial assessment in our clinics. The mean follow-up duration ± SD in the ICA was 3.3 ± 4.1 years (range: 1-18 years). Other risk factors and organ damage are reported in Table 1 . Cardiovascular complications were left ventricular hypertrophy (44.4%, n = 1144), heart failure (16.2%, n = 417), coronary artery disease (5.2%, n = 133), arrhythmia (4.9%, n = 127) and peripheral arterial disease (0.5%, n = 13). Echocardiography was performed in 1182 patients (45.9%) and was normal in 227 (19.2%). The recorded anomalies were left ventricular diastolic dysfunction (35.6%, n = 421), hypertensive cardiomyopathy (29.7%, n = 351) and minor lesions (slight valve regurgitation, sclerosis, valvular calcification) (11.2%, n = 133). Cardiovascular risk stratification according to the European guideline for the management of arterial hypertension is reported in Table 2 . The very high added risk and high added risk categories were predominant at presentation in 46.7% and 37.8% of patients, respectively.
In addition to lifestyle changes, 97.8% of patients received antihypertensive drugs. Among those receiving treatment for high blood pressure, the most common agents used were diuretics (59.7% of patients), followed by blockers of the renin-angiotensin system (RAS) (either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) (59.6%), calcium antagonists (25.2%), beta-blockers (23.9%) and centrally-acting sympatholytics Data are number (%). Low added risk (n = 107), moderate added risk (n = 277), high added risk (n = 974) and very high added risk (n = 1202). DBP: diastolic blood pressure; HT: hypertension; MS: metabolic syndrome; OD: subclinical organ damage; SBP: systolic blood pressure.
(6.4%). Antihypertensive drugs were used as monotherapies or in combination ( Table 3) . As a monotherapy, the most frequently prescribed drug class was calcium antagonists (34.6%) followed by RAS-blockers (31.2%). More than 66% of patients being treated for hypertension were receiving at least two antihypertensive drugs, including fixed-dose combination drugs. The most common combination of drugs among those taking two agents was a RAS-blocker plus a diuretic (66.2%), and among those taking three agents was a RAS-blocker plus a diuretic plus a calcium antagonist (52.3%).
Between the first and last visits, systolic blood pressure decreased by 20 mmHg and diastolic blood pressure by 13 mmHg. Hypertension was controlled in 43.7% of patients despite detectible culprit factors influencing blood pressure control (age, weight, body mass index and presence of left ventricle hypertrophy; Table 4 ). The therapeutic approach also had an impact on blood pressure control; the most effective monotherapies were calcium antagonists followed by diuretics, then beta-blockers and RAS-blockers (Table 5) . Finally, combination therapy, including the association of RAS-blocker with a diuretic, produced a better reduction in systolic blood pressure compared with other combinations that excluded both RAS-blockers and diuretics (Table 5) .
For statistical analysis, centrally-acting sympatholytics were ignored because of their infrequent use. Among monotherapy regimens, there was a statistically significant difference between antihypertensive drugs in terms of lowering SBP: F = 13.868, P < 0.01; calcium antagonists were the most effective compared with beta-blockers (P < 0.01), RAS-blockers (P < 0.01) and diuretics (P < 0.01); second in line came diuretics compared with beta-blockers (P < 0.01) and RAS-blockers (P < 0.01); there were no statistically significant differences between the effects of RAS-blockers and beta-blockers on SBP (P = 0.08). In contrast, there were no statistically significant differences between the various antihypertensive classes in terms of reduction in DBP (F = 0.11, P = 0.95). Among the polytherapy regimens, patients who received a RAS-blocker + diuretic combination had significantly higher SBP at initiation of therapy (P < 0.01) and this combination was more effective at controlling SBP compared with other combination therapies (P < 0.01).
Discussion
The primary goal of treatment of the hypertensive patient is to achieve the maximum reduction in the long-term total risk of cardiovascular morbidity and mortality. This requires treatment of all the reversible risk factors identified, including smoking, dyslipidaemia, abdominal obesity or diabetes [7, 13] . Antihypertensive treatment translates into significant reductions in cardiovascular morbidity and mortality [14] [15] [16] [17] . We observed a blood pressure level that was too high among our patients; hypertension stage 3 was observed in 46% of patients. As has been previously described, it is suggested that Black Africans present with more severe forms of arterial hypertension and a greater risk of target organ damage [18] [19] [20] [21] . Over 74% of our patients had organ damage. Furthermore, significant comorbidities, such as diabetes, were found in 12.2%. All of this contributed to the important rates of very high (46.7%) or high (37.8%) added cardiovascular risk that we observed. An Italian study using the ESH/ESC classification for cardiovascular risk stratification found a very high added risk in 9.7%, a high added risk in 19.8%, a moderate added risk in 23.7% and a low added risk in 46.8% of patients [22] . In a cross-sectional study of hypertension conducted among civil servants in Accra (Ghana), target organ damage was present in 47.5% of the participants, with a 9.1% prevalence of diabetes [11] . Overall, uncontrolled blood pressure remains the main factor for target organ damage, at highest extent in SSA compared with Western countries [23] .
The main benefits of antihypertensive treatment are blood pressure lowering per se, largely independent of the drugs employed. Diuretics, beta-blockers, calcium antagonists and RAS-blockers can adequately lower blood pressure, significantly improving cardiovascular outcome [24] . All these drugs are considered suitable for the initiation and maintenance of treatment, either as monotherapy or in combination therapeutic regimens. In our series, monotherapy consisted mainly of calcium antagonists and RAS-blockers. Given the importance of organ damage in our cohort, these drugs were highly appropriate. Calcium antagonists, besides being effective for left ventricular hypertrophy, appear beneficial in slowing the progression of carotid hypertrophy and atherosclerosis [25, 26] . RASblockers have been reported to be particularly effective in reducing left ventricular hypertrophy, in reducing microalbuminuria and proteinuria, in preserving renal function and delaying renal disease [27] [28] [29] [30] [31] . This is also the reason why diuretics, although the most prescribed drugs, were most usually used in combination rather than alone in our hypertensive patients. Although the overall benefits/harm of centrally-acting antihypertensive drugs remain unproven, they were still used in our context [7] . They were mainly used in adjunctive regimens. Centrally-acting drugs are less expensive than other antihypertensive drugs, which represents a particular advantage in our context.
More than two-thirds of hypertensive patients are unsatisfactorily controlled with monotherapy, according to the Joint National Committee VII report [13] , as they require two or more antihypertensive drugs. Our findings are consistent with this report, as over 66% of our patients required at least two drugs to achieve blood pressure control. The combination drugs we used were commonly a RAS-blocker plus a diuretic. Recommendations state that the drugs to be combined should have different and complementary mechanisms of action. The blood pressure lowering effect of the combination should be greater than that of the combination components, possibly also with a reduction in their side effects. The combination should also have a greater protective effect on organ damage. The combination of a RAS-blocker plus a diuretic satisfies all these criteria [32] .
In a previous short series, low compliance with antihypertensive treatment was recorded among our patients [33] . The causes were numerous: no medical insurance, unemployed patients, high cost of drugs and a high number of daily tablets required (more than three), among other causes. A population-and economics-specific context must be taken into account when prescribing long-term medication. The process of buying the drug can be complex, involving African family solidarity. For instance, it is quite common that the person purchasing the medication is a family member rather than the patient.
We consider that the rate of blood pressure control was very acceptable in our context (43%). Whereas our results report data from the reference centre in Côte d'Ivoire, it is inappropriate to extrapolate to a national level in Côte d'Ivoire. This health problem is usually managed mostly by a general practitioner, or by a local nurse in rural areas. Given optimal conditions with appropriate management in a referral centre, blood pressure control can be similar to that reported in Western series (31-46% in Europe and 63% in the USA) [34] . While studies from other African nations showed lower blood pressure control (29% in Kenya [35] ; 11.4% in Ghana [11] ), improvement in the rate of target blood pressure attainment continues in England, for example, where it rose from 46% in 2003 to 52% in 2006 [36] .
Our data provide another line of evidence that diuretics and calcium antagonists are optimal monotherapy choices for the control of hypertension in Africans. As previously demonstrated, RAS-blockers are less useful in treating African hypertensive patients due to low plasma renin activity in this population [37] [38] [39] . Our observation supports this, as RAS-blocker monotherapy led to poor blood pressure control in our cohort. Fortunately, when associated with a diuretic, the resulting blood pressure reduction improved. We therefore suggest avoiding RAS-blockers as monotherapy in the treatment of hypertension in Africans. When a RAS-blocker is necessary due to known comorbidities, we recommend its combination with a diuretic [27] [28] [29] [30] [31] .
Study limitations
There were a number of limitations to this study. Firstly, other behavioural measures, such as increased physical exercise, decreased obesity, cessation of smoking and limiting alcohol consumption, are important for the control of hypertension. In our retrospective study, such data were difficult to document. In the same way, control of other modifiable cardiovascular risk factors (diabetes, dyslipidaemia), which is essential in the management of hypertension, was overlooked. Secondly, this cross-sectional study did not attempt to assess the occurrence of complications of hypertension during the follow-up period. The main limitation from a methodological standpoint was that our study was limited to cases with regular follow-up, which basically excluded patients who were unlikely to comply with medication. The most regular hypertensive patients at the ICA were very likely to be aware of their illness and compliant with treatment, which may represent a bias in the selection criteria.
Conclusion
Given the appropriate social and medical environment, it is possible to achieve optimal blood pressure in Côte d'Ivoire, similar to that in economically wealthy Western countries. This was particularly true in high-risk patients. Our data should encourage local and neighbouring authorities to plan and implement public health policies in this direction.
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